Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous vedolizumab in pediatric ulcerative colitis or Crohn's disease
NL-OMON60641Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of vedolizumab in autoimmune colitis and Crohn's disease (2 arms), sponsored by Takeda. Primary endpoints: Ctrough,ss and Cavg,ss. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON60641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60641.